Telatraz Plus Dosage/Direction for Use

Recommended Dosage: Adults: TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET should be taken once daily. The dose of telmisartan could be up-titrated before switching to TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET. Direct change from monotherapy to the fixed combinations may be considered.
TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET 40/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by telmisartan 40 mg or hydrochlorothiazide.
TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET 80/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by telmisartan 80 mg or by TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET 40/12.5 mg.
TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET 80/25 mg may be administered in patients whose blood pressure is not adequately controlled by Telmisartan and Hydrochlorothiazide tablets 80 mg/12.5 mg.
The maximum antihypertensive effect is generally attained with TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET 4-8 weeks after the start of treatment.
When necessary, TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET may be administered with another antihypertensive drug.
In patients with severe hypertension treatment with telmisartan at doses up to 160 mg alone and in combination with hydrochlorothiazide 12.5-25 mg daily was well tolerated and effective.
TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET may be taken with or without food.
Renal impairment: Due to the hydrochlorothiazide component, TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET should not be used in patients with severe renal dysfunction (creatinine clearance <30 mL/min). Loop diuretics are preferred to thiazides in this population. Experience in patients with mild to moderate renal impairment is not modest but has not suggested adverse renal effects and dose adjustment is not considered necessary. Periodic monitoring of renal function is advised.
Hepatic impairment: In patients with mild to moderate hepatic impairment the posology should not exceed TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET 40/12.5 mg once daily. TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function.
Elderly: No dose adjustment is necessary.
Children and adolescents: Safety and efficacy of TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLET have not been established in children and in adolescents up to 18 years.
Route of Administration: Solid Oral.